Ovarian cancer cells may quickly activate a survival response after PARP inhibitor treatment, and blocking this early response may make this class of drugs work better, a study published by Mayo Clinic researchers suggests.
Diaceutics has released research revealing a critical shift in precision medicine. Despite major advances in biomarker testing, nearly two-thirds of eligible patients with advanced non-small cell lung cancer in the U.S. are still not receiving the most appropriate treatment.
